Finance 4h ago 1 min read
AstraZeneca $AZN fell 9%, erasing roughly $27B in market value, after Wainua missed the primary endpoint in a late-stage ATTR-CM heart trial. The miss puts a larger cardiac indication behind the drug under pressure while existing approvals remain intact.